10x Genomics CFO sells 46,388 shares in plan

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold a total of 46,388 shares of Class A Common Stock on September 9, 2026 in three open-market transactions at weighted average prices ranging from about $63.68 to $65.26, under a Rule 10b5-1 trading plan adopted on June 10, 2026.

Insider Trade Summary 10b5-1

Net Seller: 46,388 shares

Net Sell 3 txns

Insider Taich Adam

Role Chief Financial Officer

Sold 46,388 shs ($3.00M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	1,206	$63.6774	$77K
Sale	Class A Common Stock F1, F3	31,428	$64.3097	$2.02M
Sale	Class A Common Stock F1, F4	13,754	$65.2574	$898K

Holdings After Transaction: Class A Common Stock — 316,344 shares (Direct)

Footnotes (4)

1. F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026.
2. F2. This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Total shares sold: 46,388 shares First tranche sold: 1,206 shares at $63.6774 Second tranche sold: 31,428 shares at $64.3097 +2 more

5 metrics

Total shares sold 46,388 shares Aggregate Class A Common Stock sales by CFO on September 9, 2026

First tranche sold 1,206 shares at $63.6774 Class A Common Stock sale on September 9, 2026; weighted average price

Second tranche sold 31,428 shares at $64.3097 Class A Common Stock sale on September 9, 2026; weighted average price

Third tranche sold 13,754 shares at $65.2574 Class A Common Stock sale on September 9, 2026; weighted average price

Rule 10b5-1 plan adoption date June 10, 2026 Date CFO’s trading plan governing these sales was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Class A Common Stock financial

"security title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TXG’s CFO report on this Form 4?

The Chief Financial Officer, Adam Taich, reported selling a total of 46,388 shares of 10x Genomics Class A Common Stock on September 9, 2026 in three open‑market transactions.

At what prices did the TXG shares sell in the CFO’s September 9, 2026 trades?

The reported weighted average sale prices were $63.6774 for 1,206 shares, $64.3097 for 31,428 shares, and $65.2574 for 13,754 shares, each executed in multiple trades within stated price ranges.

How many TXG shares did the CFO sell in total on September 9, 2026?

Adam Taich sold a total of 46,388 shares of 10x Genomics Class A Common Stock on September 9, 2026, based on the aggregated sell-share count reported in the Form 4.

Were the TXG CFO’s reported share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to Adam Taich’s Rule 10b5‑1 trading plan, which was adopted on June 10, 2026.

How were the TXG CFO’s sale prices for each transaction calculated?

Each reported price is a weighted average sale price. Footnotes explain that the sales occurred in multiple trades within specified price ranges, and that full trade‑by‑trade details are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:48 PM Accepted by SEC EDGAR 09/11/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/09/2026		S(1)		1,206	D	$63.6774(2)	361,526	D
Class A Common Stock	09/09/2026		S(1)		31,428	D	$64.3097(3)	330,098	D
Class A Common Stock	09/09/2026		S(1)		13,754	D	$65.2574(4)	316,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 10, 2026.

2. This transaction was executed in multiple trades at prices ranging from $63.67 to $63.83, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $64.01 to $64.87, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $64.88 to $65.875, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for Adam Taich	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)